Atherosclerosis of the thoracic aorta and XXXX as a marker of poor prognosis: benefit of oral anticoagulants.

@entity1 @entity64 @entity887 @entity1031 @entity2333 @entity204 @entity1856
OBJECTIVES: Our aim was to confirm the poor prognosis related to thoracic aortic plaques, in particular @entity2333 , diagnosed by transesophageal echocardiography (TEE) and to evaluate @entity1 ' prognosis as a function of the antithrombotic treatment. BACKGROUND: @entity1856 ( @entity1856 ) has been widely studied. However, it is still not known which antithrombotic treatment should be adopted in this disease. METHODS: @entity1 referred for TEE and diagnosed with @entity1856 were followed. All @entity1031 events and @entity204 were recorded during a follow-up of 22+/-10 months. The antithrombotic treatment to be adopted was left to the discretion of the practitioner in charge of the @entity1 . RESULTS: @entity1856 was found in 12% of all TEE performed and in 27.5% of TEE performed for @entity64 . This prevalence was higher when no other etiology existed to explain the @entity64 (p < 0.001). During follow-up, an end point occurred in 22.5% of @entity1 . The more severe the @entity1856 the greater the incidence of events (p = 0.007). A higher mortality rate is shown in @entity1 with @entity2333 (p = 0.049). Compared with those treated with oral anticoagulants, @entity1 with aortic plaques >4 mm thick treated with antiplatelets had more @entity887 and combined events (p = 0.01 and p = 0.007, relative risk [RR] = 5.9, 95% confidence interval [CI] = 1.4 to 15, respectively); @entity1 with @entity2333 had more combined events and a higher mortality rate (p = 0.001, RR = 7.1, 95% CI = 1.2 to 19 and p = 0.019, RR = 9.1, 95% CI = 1.2 to 25, respectively). CONCLUSIONS: We confirm the high incidence of vascular events and @entity204 in @entity1 with @entity1856 . We have demonstrated, for the first time in this condition, a better outcome among @entity1 treated with oral anticoagulants versus antiplatelets.
